First Cannabinoid-Based Rapid Seizure Cessation Formulation Patent Granted to Colorado Startup
DENVER, CO, March 05, 2019 -- JC Pharma Inc. (Boulder, CO) was recently awarded a US Patent (US10206901B2) entitled, "Method and composition for acute treatment of seizures" for its Cannabis sativa-derived intranasal formulation used to terminate ongoing seizure activity in epilepsy and self-injurious behavior in autistic children. With this patent and the Cannatol product line JC is following in the footsteps of GW Pharmaceuticals (NASDAQ:GWPH) and their pioneering FDA approved cannabis-derived drug, Epidiolex.
